VOSE vs. MOSE in EUS-FNB for Pancreatic Masses
Comparison of Specimen Quality Using Visual On-Site Evaluation Versus Macroscopic On-Site Evaluation in Endoscopic Ultrasound-Guided Fine Needle Biopsy of Solid Pancreatic Masses: A Prospective, Multicenter, Randomized Controlled, Non-Inferiority Trial
The primary endpoint of this study was to evaluate whether the histopathological diagnostic accuracy of VOSE EUS-FNB using 22-gauge (22G) Franseen or 22G Trident (Trident™) needles is non-inferior to that of MOSE EUS-FNB in pancreatic solid masses. The secondary endpoints included diagnostic sensitivity, diagnostic specificity, median number of needle passes, puncture time, and cytological diagnostic accuracy.
研究概览
地位
地位
干预/治疗
干预/治疗
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 不适用
联系人和位置
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200025
- Ruijin hospital
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age above 18 years, male or female.
- Presence of a solid pancreatic mass detected by CT, MRI, PET-CT, or EUS, and scheduled for EUS-FNB for diagnostic purposes.
- Provision of signed written informed consent.
Exclusion Criteria:
- Contraindications to endoscopy, such as severe cardiovascular or cerebrovascular diseases.
- Coagulation disorders (International Normalized Ratio [INR] ≥ 1.5, platelet count ≤ 50 × 10^9/L) or current use of anticoagulant or antiplatelet medications.
- Confirmed or suspected pregnancy.
- Pathological diagnosis has already been established by other methods.
- Refusal to participate in the study, current participation in another clinical trial, or participation in another clinical trial within 60 days prior to enrollment.
- Any other conditions that preclude the performance of EUS-FNB.
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:VOSE Group (Visual On-Site Evaluation)
Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and visible tissue cores are placed into formalin for visual grading. If no "red mixed specimen" is observed, additional passes are performed up to 3 passes. The number of passes and puncture time are recorded. |
VOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide. Visible tissue cores are placed into a formalin vial, gently shaken to dissolve blood, and visually graded with photographic recording. If the first-pass specimen is not a "red mixed specimen," additional passes are performed until a "red mixed specimen" appears or a maximum of 3 passes is reached. |
|
有源比较器:MOSE Group (Macroscopic On-Site Evaluation)
Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and the macroscopic visible core (MVC) length is measured. If the MVC is < 10mm, additional passes are performed until the total MVC is ≥ 10mm or up to 3 passes. The number of passes and puncture time are recorded. |
MOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide, and the length of the macroscopic visible core (MVC) is measured. If the total MVC length is less than 10 mm, additional passes are performed until the total MVC is ≥ 10 mm or a maximum of 3 passes is reached. |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Histopathological diagnostic accuracy
大体时间:Within 30 days after the EUS-FNB procedure
|
The diagnostic accuracy of histopathological tissue obtained by EUS-FNB in the VOSE group compared to the MOSE group, using the final surgical pathology or clinical/radiological follow-up as the gold standard. |
Within 30 days after the EUS-FNB procedure
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Diagnostic sensitivity
大体时间:Within 30 days after the EUS-FNB procedure
|
The diagnostic sensitivity of VOSE and MOSE groups compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
|
Diagnostic specificity
大体时间:Within 30 days after the EUS-FNB procedure
|
The diagnostic specificity of VOSE and MOSE groups compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
|
Median number of needle passes
大体时间:During the EUS-FNB procedure
|
The number of needle passes required to obtain adequate tissue samples (until a "red mixed specimen" or MVC ≥ 10mm is observed, up to 3 passes). |
During the EUS-FNB procedure
|
|
Puncture time
大体时间:During the EUS-FNB procedure
|
The duration of the puncture procedure (from the start of the first needle pass to the end of sampling). |
During the EUS-FNB procedure
|
|
Cytological diagnostic accuracy
大体时间:Within 30 days after the EUS-FNB procedure
|
The diagnostic accuracy of liquid-based cytology obtained from residual specimens in VOSE and MOSE groups, compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
合作者和调查者
合作者
合作者
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他研究编号
其他研究编号
- RJ2026164
- 82570763 (其他赠款/资助编号:National Nature Science Foundation of China)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.